Genmab A/S (GMAB)

On March 20, Caroline Woods from The Street sat down with Mo Haghbin, Managing Director at ProShares, to break down where the money is actually going amid a market dealing with rising geopolitical tensions...

Genmab (NASDAQ:GMAB) is one of the best NASDAQ growth stocks to buy for the next 2 years. On February 17, Genmab reported that its total revenue grew by 19% in 2025 to a total $3.7 billion.

On February 19, Tom Lee of Fundstrat and BitMine joined 'Closing Bell' on CNBC to talk about the state of the markets.

Operator: Hello, and welcome to the Genmab Full Year 2025 Financial Results Conference Call. As a reminder, this conference call is being recorded.

​On February 10, Peter Boockvar, Chief Investment Officer at BFG Wealth Partners, appeared on a CNBC television interview.

Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks under $50 to invest in.

On January 27, Jared Holz, healthcare equity strategist at Mizuho, appeared on CNBC’s 'Power Lunch' to talk about healthcare stocks and the new proposals around Medicare Advantage.

Genmab A/S (NASDAQ:GMAB) ranks among the best high growth European stocks to buy. On January 20, H.C.

European equities began the last week of January in a sour mood, with investors concerned on January 26 about rising geopolitical tensions in anticipation of a Federal Reserve policy meeting and a flood...